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A B S T R A C T
Based on the results of randomized multicenter studies, such as the MADIT I, MA-
DIT II, DINAMIT, and SCD-HeFT and DEFINITE trials, patients can be identified 
who are at high risk for sudden cardiac death (SCD) who demonstrate a reduction 
in arrhythmic mortality and total mortality with the implantation of an implantable 
cardioverter defibrillator (ICD). These are patients with coronary artery disease, im-
paired left ventricular function, spontaneous nonsustained ventricular tachycardia 
and inducible ventricular tachycardia not suppressed by procainamide. Also patients 
with coronary artery disease and left ventricular ejection fraction <30% benefit from 
ICD placement. Based on the SCD-HeFT results, patients with ischemic or nonisch-
emic cardiomyopathy and class II or III congestive heart failure also benefit from the 
ICD. At the same time, based on the results of the DINAMIT study, it has become 
apparent that the ICD does not play a role in patients within 45 days of myocardial 
infarction. The implications of these trials are further analyzed in this overview.
I N T R O D U C T I O N
Sudden cardiac death (SCD) remains the most common cause of death in every 
industrialized nation, with over 300,000 deaths each year in the United States alone. 
Prediction and prevention of SCD has been the objective of multiple trials evaluating 
techniques of risk stratification and antiarrhythmic agents. Epidemiological studies 
indicate that more than half of the mortality from cardiovascular disease is sudden. 
In 1991, publication of the Cardiac Arrhythmia Suppression Trial (CAST) highlighted 
the adverse mortality effects with traditional antiarrhythmic agents.1 This landmark 
trial served as the impetus for the development of appropriately designed trials to 
assess the efficacy of the implantable cardioverter defibrillator (ICD) in improving 
survival in patients at high risk for SCD with ischemic heart disease. It is with this 
background that ICDs were evaluated in patients with coronary artery disease with a 
high risk of SCD in the MADIT I and MADIT II trials.2-4 More recently, evaluation 
of the role of the ICD for prevention of SCD has been evaluated in the DINAMIT, 
SCD-HeFT and DEFINITE Trials.5-7
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R E C E N T  T R I A l S
The MADIT I study was designed as a proof of concept 
study to determine through a randomized trial if an ICD could 
result in improved survival in coronary artery disease patients 
at high risk for sudden death when compared to conventional 
medical therapy.2 A total of 19 patients were enrolled in 
MADIT I during a four-year period selected based on a left 
ventricular ejection fraction (LVEF) ≤35%, spontaneous non-
sustained ventricular tachycardia, and inducible ventricular 
tachycardia not suppressed by procainamide. The MADIT 
I trial showed a 54% reduction in the risk of sudden death 
compared to patients who did not receive the ICD and were 
treated with amiodarone. Based on this study the Food and 
Drug Administration approved the ICD in the United States 
for such patients with a MADIT I indication in 199. Second-
ary investigations were performed to evaluate ICD efficacy 
in multiple high risk subsets, including those with an LVEF 
<25%, QRS duration >0.12 seconds, and those with conges-
tive heart failure. These analyses revealed that the sicker 
patients achieved more benefit from the ICD.4 It was based on 
these findings that the MADIT II trial was designed.3
The rationale for MADIT II trial was that by selecting 
patients with coronary artery disease and advanced left ven-
tricular dysfunction (LVEF ≤30%), there would be sufficient 
myocardial scar to provide the substrate for malignant arrhyth-
mias.3,4 The MADIT II trial enrolled patients based selected 
solely on the presence of coronary artery disease and LVEF 
<30% with no arrhythmia qualifier. In this patient popula-
tion, the mean LVEF was 23%. The ICD was associated with 
a 31% risk reduction for total mortality compared to patients 
not receiving the ICD. Importantly, approximately 70% of 
both treatment groups received optimal medical therapy with 
beta-blockers and angiotensin converting enzyme inhibitors. 
In long-term follow-up there is a 40% cumulative probability 
of appropriate ICD therapy for ventricular tachycardia or 
ventricular fibrillation during four years after ICD implant.
Substudy analyses of the MADIT II patients were per-
formed and the patients were stratified into four groups based 
on their baseline ECG.4 These included (1) pacemaker related 
wide QRS complex; (2) intrinsic QRS ≤0.12 seconds; (3) in-
trinsic QRS 0.12 seconds to 0.15 seconds, (4) intrinsic QRS 
≤0.15 seconds. The hazard ratio in patients with a pacemaker 
was 0.99 indicating no benefit from ICD therapy. The ICD 
was associated with progressively lower hazard ratio (greater 
ICD efficacy) with greater increased intrinsic QRS duration, 
although the beneficial trend was not significantly different 
within the three QRS groups.
An important issue related to these findings relates to the 
value of electrophysiology testing in patients with randomized 
ICD therapy.4 Electrophysiology testing was performed in 593 
patients randomized to the ICD, and 3% of the patients were 
found to have inducible ventricular tachycardia or ventricular 
fibrillation using standard induction protocol and traditional 
criteria for inducibility.4 In this group of patients, the clinical 
significance of inducibility and non-inducibility before or at 
ICD implantation was evaluated in terms of appropriate use 
of ICD. Patients who had inducible ventricular tachycardia at 
electrophysiology testing had significantly increased utilization 
of ICD therapy for documented ventricular tachyarrhythmias 
than those who had no inducible arrhythmias. However, the 
latter patients had significantly increased utilization of ICD 
therapy with documented ventricular fibrillation than those 
who had inducible ventricular tachycardia. The noninducible 
patients were significantly sicker than the inducible patients 
in terms of more advanced New york Heart Association 
(NyHA) class, higher blood urea nitrogen values, and lower 
use of beta-blockers. Among 29 patients who had documented 
episodes of ventricular fibrillation recorded by the ICD, 83% 
of the recorded ventricular fibrillation events were in the 
noninducible group.4
More recently in the DINAMIT study, patients with a 
recent myocardial infarction (MI) were studied relative to 
benefit of the ICD. DINAMIT was designed to test single 
chamber ICD therapy in patients who had an MI within the 
previous  to 45 days, LVEF ≤35%, and low heart rate vari-
ability.5 Researchers enrolled 74 patients at 73 centers in 10 
countries and randomized them in an open label fashion to 
ICD therapy or control. All patients received best medical 
therapy with 80% receiving beta blockers, 90% receiving an-
giotensin converting enzyme (ACE) inhibitors, 75% receiving 
lipid lowering drugs, and 90% receiving antiplatelet therapy.
The mean age of the patients was 1 years. Overall, 39% 
received thrombolytic therapy and the mean LVEF was 28%. 
The mean time since the MI was 18 days. About one third 
of the patients had a MI prior to the index event and a small 
number had a prior angioplasty. The patients were followed 
for 2.5 years to assess mortality rates. It was determined that 
an overall mortality of 17.8% in 30 months, or about 7% per 
year, was present with no difference between the two treatment 
groups. However, when arrhythmic and nonarrhythmic deaths 
were analyzed separately, researchers noted a significant 
increase in nonarrhythmic deaths in the ICD group (hazard 
ratio-HR 1.75; 95% confidence intervals-CI 1.11-2.7) as well 
as a significant decrease in the arrhythmic deaths (HR 0.42; 
95% CI 0.22-0.83). Further subanalysis divided these patients 
into three groups, those who were randomized with no ICD, 
those who received an ICD but had no shocks, and those who 
got an ICD with appropriate shocks. It was determined that 
among the ICD patients, those receiving appropriate shocks 
(55 patients) had a 15.4% annual risk of nonarrhythmic death, 
compared to 3.9% mortality risk in ICD patients who did not 
receive appropriate shocks (257 patients).
SCD-HeFT was a trial comparing three separate arms 
with placebo and optimal medical therapy, amiodarone and 
optimal medical therapy, and ICD to optimal medical therapy 
in patients with ischemic and nonischemic cardiomyopathy. 
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A total of 2521 patients with ischemic cardiomyopathy (51%) 
or nonischemic dilated cardiomyopathy (49%) were enrolled. 
The inclusion criteria included symptomatic heart failure, 
NyHA class II or III for at least three months in the presence 
of a LVEF ≤35% despite optimal medical therapy including 
ACE inhibitors and beta blockers. SCD-HeFT had a 90% 
probability of detecting a 25% mortality reduction by ICD 
therapy. This was based on the assumption of a total mortality 
of 25% in the placebo arm in 2.5 years with 50% of deaths be-
ing due to arrhythmias. The major finding of SCD-HeFT was 
significant reduction in the total mortality in the ICD group, 
whereas amiodarone did not improve survival. A subgroup 
analysis revealed a similar survival benefit in the ICD group 
of patients with ischemic cardiomyopathy compared to patients 
with nonischemic cardiomyopathy. Due to these results and 
due to high power SCD-HeFT as a randomized control trial, 
currently available guidelines for prophylactic ICD therapy 
are being reevaluated in the United States.
An important sub-study of the SCD-HeFT trial dem-
onstrated that electrocardiogram measurements can not be 
used to predict who will benefit from an ICD therapy.7 This 
analysis of the SCD-HeFT patients was performed based on 
the width of QRS interval. The secondary analysis of the elec-
trocardiographic data demonstrated that patients who have 
a QRS duration of at least 0.12 seconds and receive an ICD 
had a 33% reduction of relative risk of all cause mortality in 
five years, compared with similar patients on medical therapy. 
However, the 59% of SCD-HeFT patients with a QRS <0.12 
seconds, also had clinically and statistically significant 1% 
reduction mortality with the ICD. Redefining a narrow QRS 
as 0.12 seconds or less, the population that benefits more from 
ICD therapy becomes SCD-HeFT group with a narrow QRS 
not a wide one. The patients with QRS of 0.12 seconds or less 
showed a 2% reduction in all cause mortality compared with 
the 20% relative reduction in patients who have a QRS >0.12 
seconds. Accordingly, no particular QRS duration provides 
sufficient specific risk categorization to select or exclude pa-
tients for ICD therapy. Clinical trials investigators have taken 
issue which what they view as a post hoc data analysis on a part 
of officials in the United States in approving reimbursement 
for ICDs in patients with QRS width >0.12 seconds.
The DEFINITE trial focused on a patient population with 
nonischemic dilated cardiomyopathy and LVEF of ≤30% and 
premature ventricular complexes or nonsustained ventricular 
tachycardia.8 A total of 229 patients were randomly assigned 
to receive standard medical therapy, and 229 to receive the 
medical therapy plus single chamber ICD. The patients were 
followed for a mean of 29.0±14.4 months. The mean LVEF 
was 21%. A vast majority of patients were treated with ACE 
inhibitors (8%) and beta blockers (85%). There were 8 
deaths: including 28 in the ICD group, as compared to 40 in 
the standard therapy group. The mortality rate at two years 
was 14.1% in the standard therapy group and 7.9% in the ICD 
group (P=0.0). There were 17 sudden deaths from arrhyth-
mia including three in the ICD group, and 14 in the standard 
group. It was concluded based on the DEFINITE Trial in 
patients with severe, nonischemic dilated cardiomyopathy, 
who were treated with ACE inhibitors and beta blockers, the 
implantation of an ICD significantly reduced the risk of sud-
den death from arrhythmia. The ICD also was associated with 
a nonsignificant risk reduction for all cause mortality.
C O N C l U S I O N
Based on the results of the MADIT I, MADIT II, DINA-
MIT, and SCD-HeFT and DEFINITE trials, patients can be 
identified who are at high risk for sudden cardiac death who 
demonstrate a reduction in arrhythmic mortality and total 
mortality with the implantation of an ICD. This includes pa-
tients with coronary artery disease, impaired left ventricular 
function, spontaneous nonsustained ventricular tachycardia 
and inducible ventricular tachycardia not suppressed by 
procainamide. Also patients with coronary artery disease 
and LVEF <30% benefit from ICD placement. Based on the 
SCD-HeFT results, patients with ischemic or nonischemic 
cardiomyopathy and class II or III congestive heart failure also 
benefit from the ICD. At the same time, based in DINAMIT, 
it has become apparent that the ICD does not play a role in 
patients within 45 days of myocardial infarction.
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